Edition:
India

Natera Inc (NTRA.OQ)

NTRA.OQ on NASDAQ Stock Exchange Global Select Market

17.12USD
10 Dec 2018
Change (% chg)

$0.15 (+0.88%)
Prev Close
$16.97
Open
$17.13
Day's High
$17.42
Day's Low
$16.63
Volume
136,141
Avg. Vol
255,626
52-wk High
$29.53
52-wk Low
$8.60

Summary

Name Age Since Current Position

Matthew Rabinowitz

45 2015 Chairman of the Board, President, Chief Executive Officer, Co-Founder

Jonathan Sheena

45 2007 Co-Founder, Chief Technology Officer, Director

Michael Brophy

38 2017 Chief Financial Officer

Steven Chapman

39 2017 Chief Operating Officer

Paul Billings

64 2018 Chief Medical Officer and Senior Vice-President of Medical Affairs

Roelof Botha

44 2007 Lead Independent Director

Roy Baynes

2018 Director

Herman Rosenman

70 2017 Director

Todd Cozzens

62 2007 Independent Director

Edward Driscoll

65 2007 Independent Director

James Healy

53 2014 Independent Director

Gail Marcus

61 2017 Independent Director

John Steuart

56 2007 Independent Director

Biographies

Name Description

Matthew Rabinowitz

Dr. Matthew Rabinowitz, Ph.D. serves as Chairman of the Board, President, Chief Executive Officer and Co-Founder of the Company. Dr. Rabinowitz is a co-founder of our company and has served as a member of our board of directors and as our Chief Executive Officer since 2005 and as Chairman of our board of directors since May 2015. Prior to co-founding our company, Dr. Rabinowitz served from 2000 to 2003 as chief executive officer and from 2003 to 2007 as chief technology officer of Rosum Corporation, a location services technology company. Dr. Rabinowitz has multiple publications in signal processing, machine learning, bio-informatics, and high-throughput genetic testing. He received the Scott Helt Memorial Award from the Institute of Electrical and Electronics Engineers and received Technology Pioneer Awards from the World Economic Forum for founding Rosum Corporation and Natera. He currently serves on the board of directors of a private company. Dr. Rabinowitz holds a Bachelor of Science degree in Engineering and Physics, a Master of Science in Electrical Engineering, and a Ph.D. in Electrical Engineering, from Stanford University.

Jonathan Sheena

Mr. Jonathan Sheena serves as Co-Founder, Chief Technology Officer and Director of the Company. In 1999, Mr. Sheena co-founded PhoneSpots, Inc. (formerly PocketThis, Inc.), a mobile technology company serving mobile carriers worldwide. Mr. Sheena holds a Bachelor of Science in Electrical Engineering and Computer Science, and a Master of Engineering in Electrical Engineering and Computer Science, from the Massachusetts Institute of Technology.

Michael Brophy

Mr. Michael Burkes Brophy serves as Chief Financial Officer of the Company. Mr. Brophy has served as our Chief Financial Officer since February 2017. Previously, he served as our Senior Vice President, Finance and Investor Relations since September 2016, and prior to that, as our Vice President, Corporate Development and Investor Relations since September 2015. Prior to joining Natera, Mr. Brophy served as an executive director from January 2014 to September 2015, and as a vice president from 2011 to 2013, in the investment banking division at Morgan Stanley where he focused on advising corporate clients in the life science tools and diagnostics sector. Mr. Brophy holds an M.B.A. from the University of California, Los Angeles and a Bachelor of Science in Economics from the United States Air Force Academy.

Steven Chapman

Mr. Steven Leonard Chapman is Chief Operating Officer of the company ,since July 2017. he served as Senior Vice President - Commercial Operations of Natera, Inc. Mr. Chapman began his career in the Department of Human Genetics at UCLA, where he contributed to the selection process and design of oligonucleotide arrays used to identify SNPs associated with multiple sclerosis. After leaving UCLA, Mr. Chapman worked in a commercial role with Genzyme Genetics, where his team was responsible for prenatal and preconception genetic testing revenues nearing $100 million. During his time at Genzyme, Mr. Chapman’s efforts reshaped the way medicine is practiced when he led Genzyme’s sales initiative into population screening for Fragile X Syndrome. He established the largest global network of physicians who routinely screen for the disorder, and radically altered the way the test is offered. In 2005, he elevated carrier screening for Spinal Muscular Atrophy (SMA) to the forefront of business development efforts at Genzyme, playing a critical role in the groundbreaking launch of SMA carrier screening. Today, SMA screening is recommended by the ACMG and is routinely offered to couples across the United States. At Genzyme, Mr. Chapman was the direct recipient of 27 sales awards and was a two-time winner of the prestigious Alpine Award, which recognizes outstanding achievement and innovation. Since joining Natera in 2010, he has been responsible for building Natera’s sales and managed-care teams and has also led the commercial team. He has also overseen the successful launch of five products and the establishment of the premier worldwide distribution network for noninvasive prenatal testing. Mr. Chapman graduated with honors and holds a B.S. in Microbiology, Immunology, and Molecular Genetics from University of California, Los Angeles.

Paul Billings

Dr. Paul R. Billings is Chief Medical Officer and Senior Vice-President of Medical Affairs of the company. He is a board-certified internist and clinical geneticist with more than 30 years of experience in genomics and molecular medicine. He is the author of nearly 200 publications on genomic medicine and has held academic and research appointments atHarvard University, UC San Francisco,Stanford University, and UC Berkeley. Prior to joining Natera, Dr. Billings was Chief Medical Officer of Life Technologies, Inc., and consulting CMO of the Genetic Sciences Division of Thermo Fisher Scientific. He previously was SVP and Senior Physician at Laboratory Corporation of America Holdings. He has served on the Scientific Advisory Board of the Food and Drug Administration, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and the HHS Secretary's Advisory Committee on Genomics, Health and Society. His work formed the basis of the Genetic Information Nondiscrimination Act of 2008 (GINA).

Roelof Botha

Mr. Roelof Frederick Botha serves as lead independent director of the Company. Mr. Botha has served as a member of our board of directors since 2007. Mr. Botha has been with Sequoia Capital, a venture capital firm, since 2003, and has been a managing member of Sequoia Capital Operations, LLC since 2007. From 2000 to 2003, Mr. Botha served in a number of roles at PayPal, Inc., ultimately as the chief financial officer. Mr. Botha currently serves on the board of directors of Square, Inc., a provider of payments, financial and marketing services, and a number of private companies. Mr. Botha holds a Bachelor of Science in Actuarial Science, Economics, and Statistics from the University of Cape Town and an M.B.A. from Stanford University.

Roy Baynes

Herman Rosenman

Mr. Herman Rosenman, CPA., is the Director of the company, since February 2017. he served as Chief Financial Officer of Natera Inc. Mr. Herm Rosenman has served as our Chief Financial Officer since February 2014. Previously, he held the position of Senior Vice President—Finance and Chief Financial Officer at Gen-Probe Incorporated, a developer, manufacturer and marketer of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood, from June 2001 to April 2012, when Gen-Probe was acquired by Hologic, Inc., a developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products. From April 2012 to February 2014, Mr. Rosenman focused on his board memberships. Prior to joining Gen-Probe, he was President and Chief Executive Officer of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, from 1997 to 2000. Mr. Rosenman has served on the board of directors of Oxford Immunotec Global PLC, a commercial-stage diagnostics company, since 2013. Mr. Rosenman served on the board of directors of Medistem, Inc., a stem cell therapy company, from 2013 to 2014. Medistem, Inc. was acquired by Intrexon Corporation, a synthetic biology company. Mr. Rosenman served on the board of directors of ARYx Therapeutics Inc., a private drug discovery and development company, from 2006 to 2009. Mr. Rosenman served on the board of directors of Infinity Pharmaceuticals, Inc., a drug discovery and development company, where he served as Chairman of the Audit Committee from 2003 to 2007. He has also served on the board of directors of a number of privately held companies. Mr. Rosenman holds a B.B.A. in accounting and finance from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.

Todd Cozzens

Mr. Todd C. Cozzens is an Independent Director of the Company. Mr. Cozzens served as a member of our board of directors since 2011. Mr. Cozzens has been a managing partner at Leerink Capital Partners, an asset management firm, since 2015. Mr. Cozzens was a consultant with Sequoia Capital, a venture capital firm, from 2012 to 2015. From 2010 to 2012, Mr. Cozzens served as chief executive officer of Optum Accountable Care Solutions, a business unit of Optum/UnitedHealth Group. From 2000 to 2010, Mr. Cozzens served as chief executive officer of Picis Inc., a provider of electronic medical record software to hospitals, until its acquisition by the UnitedHealth Group in 2010. Mr. Cozzens currently serves on the boards of directors of a number of private companies. Mr. Cozzens holds a Bachelor of Arts degree from Marquette University, and completed the Program for Management Development at Harvard University.

Edward Driscoll

Dr. Edward C. Driscoll Jr. Ph.D. is an Independent Director of the Company. Dr. Driscoll has served as a member of our board of directors since 2007. Dr. Driscoll has been a partner with Decheng Capital, a venture capital firm, since October 2016, and has been a partner with Claremont Creek Ventures, a venture capital firm, since 2006, first as a venture partner, then a technology partner, and, since 2012, a director. Dr. Driscoll currently serves on the boards of directors of a number of private companies. In addition, from 2005 to 2013, Dr. Driscoll was an angel investor with Health Tech Capital, Silicom Ventures and Sand Hill Angels. From December 1995 to April 2005, Dr. Driscoll was founder, president and chief executive officer of Be Here Corporation, an internet, broadcast and videoconferencing technology company. From June 1993 to June 1995, Dr. Driscoll served as chief executive officer of Focus Surgery, Inc., a non-invasive surgical equipment company. From December 1987 to June 1993, Dr. Driscoll held various roles at Diasonics, a digital imaging and medical device company. Dr. Driscoll holds a Bachelor of Arts in Photography and Computer Science from the University of Pennsylvania, a Master of Architecture and Master of Landscape Architecture from Harvard University , and a Ph.D. in Digital Imaging from Stanford University.

James Healy

Dr. James I. Healy, M.D. PhD. is an Independent Director of the Company . He served as a member of our board of directors since November 2014. Dr. Healy has been a general partner at Sofinnova Ventures, a venture capital firm, since 2000. Prior to Sofinnova Ventures, Dr. Healy held various positions at Sanderling Ventures, a venture capital firm, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories), a research based pharmaceutical company and ISTA Pharmaceuticals, Inc., a company specializing in ophthalmic pharmaceutical products. Dr. Healy is currently on the board of directors of Ascendis Pharma A/S, a clinical-stage biopharmaceutical company; Auris Medical Holding AG, a specialty pharmaceutical company focused on tinnitus; Coherus BioSciences, Inc., a biologics platform company; Edge Therapeutics, a clinical-stage biotechnology company; Obseva SA, a clinical-stage biopharmaceutical company; and several private companies. Previously, Dr. Healy served as a board member of Anthera Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammation and autoimmune diseases; Amarin Corporation plc, a commercial-stage biopharmaceutical company; Durata Therapeutics, Inc., a pharmaceutical company focused on infectious and acute diseases; InterMune, Inc., a biotechnology company focused on orphan fibrotic pulmonary disease; KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of monoclonal antibody therapeutics; Hyperion Therapeutics, Inc., a commercial-stage orphan disease company; and a number of private companies. Dr. Healy holds a Bachelor of Arts in Molecular Biology and Scandinavian Studies from the University of California at Berkeley, and an M.D. and Ph.D. in Immunology from Stanford University School of Medicine.

Gail Marcus

Ms. Gail Boxer Marcus is an Independent Director of the Company. She joined our board of directors in March 2017. Ms. Marcus has served as a consultant and practice leader in the healthcare consulting practice of Exceptional Leaders International, a consulting company, since 2015, and as an Assistant Professor & Director of the Global Healthcare Management and Biomedical Informatics programs at the Massachusetts College of Pharmacy and Health Sciences since 2016. From 2012 to 2015, Ms. Marcus served as Chief Executive Officer and President of Calloway Laboratories, a provider of clinical toxicology laboratory services. Prior to that, Ms. Marcus held a variety of leadership roles with diagnostics, pharmacy benefit management and managed care companies. Ms. Marcus currently serves on the boards of directors of a private company and a non-profit organization, and sits on the Centers for Medicare & Medicaid Services Advisory Panel on Clinical Diagnostic Laboratory Tests. Our board of directors believes that Ms. Marcus is qualified to serve as a director based on her financial and managerial experience and service on other boards of directors. Ms. Marcus holds a Bachelor of Art in Spanish and Mathematics from Wesleyan University, an M.S.E. in Computer and Information Sciences from the University of Pennsylvania Moore School of Engineering, an M.B.A. from the Wharton School of the University of Pennsylvania, and is pursuing a Doctorate of Health Administration from the Medical University of South Carolina.

John Steuart

Mr. John D. Steuart is an Independent Director of the Company. Mr. Steuart has been a managing director at Prolog Ventures, a venture capital firm, since 2013. From 2012 to 2013, Mr. Steuart served as an independent consultant. From 2004 to 2012, Mr. Steuart served as a managing director at Claremont Creek Ventures, a venture capital firm. Mr. Steuart currently serves on the boards of directors of a number of private companies. Mr. Steuart holds a Bachelor of Science degree in Economics from the University of California, Berkeley.

Basic Compensation

Name Fiscal Year Total

Matthew Rabinowitz

3,004,930

Jonathan Sheena

990,223

Michael Brophy

1,193,540

Steven Chapman

1,627,240

Paul Billings

--

Roelof Botha

143,577

Roy Baynes

--

Herman Rosenman

116,834

Todd Cozzens

135,587

Edward Driscoll

121,087

James Healy

130,783

Gail Marcus

117,800

John Steuart

137,075
As Of  31 Dec 2017